Bavarian Nordic A/S (BAVA.CO)
24 May 2013
|Market Cap (Mil.):||kr.1,748.32|
|Shares Outstanding (Mil.):||26.09|
Jan 11 - Bavarian Nordic A/S says: * consolidates its vaccine manufacturing in Denmark * to prepare its Kvistgaard facility for the future commercial production of its prostate cancer vaccine, Prostvac, and transfer its production of clinical trial material to the facility. * to close its operations in Berlin, Germany where it has been producing clinical trial material for its MVA-BN based vaccine candidates * planned changes do not affect company expectations for 2012 full year re
Earnings vs. Estimates
Analyst Research Reports
Bavarian Nordic A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.